BackgroundPostprandial hyperglycemia is an early defect of type 2 diabetes and one of primary anti-diabetic targets. Treatment of postprandial hyperglycemia can be achieved by inhibiting intestinal α-glucosidase, the key enzyme for oligosaccharide digestion and further glucose absorption. Grape pomace is winemaking byproduct rich in bioactive food compounds such as phenolic antioxidants. This study evaluated the anti-diabetic potential of two specific grape pomace extracts by determining their antioxidant and anti-postprandial hyperglycemic activities in vitro and in vivo.MethodsThe extracts of red wine grape pomace (Cabernet Franc) and white wine grape pomace (Chardonnay) were prepared in 80% ethanol. An extract of red apple pomace was included as a comparison. The radical scavenging activities and phenolic profiles of the pomace extracts were determined through the measurement of oxygen radical absorbance capacity, DPPH radical scavenging activity, total phenolic content and flavonoids. The inhibitory effects of the pomace extracts on yeast and rat intestinal α-glucosidases were determined. Male 6-week old C57BLKS/6NCr mice were treated with streptozocin to induce diabetes. The diabetic mice were then treated with vehicle or the grape pomace extract to determine whether the oral intake of the extract can suppress postprandial hyperglycemia through the inhibition of intestinal α-glucosidases.ResultsThe red grape pomace extract contained significantly higher amounts of flavonoids and phenolic compounds and exerted stronger oxygen radical absorbance capacity than the red apple pomace extract. Both the grape pomace extracts but not the apple pomace extract exerted significant inhibition on intestinal α-glucosidases and the inhibition appears to be specific. In the animal study, the oral intake of the grape pomace extract (400 mg/kg body weight) significantly suppressed the postprandial hyperglycemia by 35% in streptozocin-induced diabetic mice following starch challenge.ConclusionThis is the first report that the grape pomace extracts selectively and significantly inhibits intestinal α-glucosidase and suppresses postprandial hyperglycemia in diabetic mice. The antioxidant and anti-postprandial hyperglycemic activities demonstrated on the tested grape pomace extract therefore suggest a potential for utilizing grape pomace-derived bioactive compounds in management of diabetes.

No abstract

Norton grape is one of the most important wine grapes in Southern and Midwestern states and generates massive pomace byproducts. The objective of this study is to characterize the antioxidant compounds and activity in Norton grape pomace extract (GPE) and further assess the potential health promoting properties of Norton GPE using an animal disease model. The total phenolic content and anthocyanins in Norton GPE were 475.4 mg of gallic acid equiv/g and 156.9 mg of cyanidin 3-glucoside equiv/g, respectively. Catechin and epicatechin in GPE were 28.6 and 24.5 mg/g, respectively. Other major antioxidants in GPE included quercetin (1.6 mg/g), trans-resveratrol (60 μg/g), gallic acid (867.2 μg/g), coutaric acid (511.8 μg/g), p-hydroxybenzoic acid (408.3 μg/g), and protocatechuic acid (371.5 μg/g). The antioxidant activity of GPE was evaluated by oxygen radical absorbance capacity (ORAC) and was 4133 μmol of Trolox equiv/g. Male diet-induced obese (DIO) mice were randomly divided to three treatment groups (n = 12): a normal diet (ND group), a high fat diet (HF group), and the high fat diet supplemented with GPE (HFGPE group). After 12-week treatment, mice in the high fat diet groups gained 29% more weight than the ND group. The GPE supplementation (estimated 250 mg/kg bw/d) lowered plasma C-reactive protein levels by 15.5% in the high fat diet fed mice (P < 0.05), suggesting a potential anti-inflammatory effect by dietary GPE. However, dietary GPE did not improve oxidative stress in DIO mice as determined by plasma ORAC, glutathione peroxidase, and liver lipid peroxidation. The results showed that GPE contained significant antioxidants and dietary GPE exerted an anti-inflammatory effect in diet induced obesity.

The epidermal growth factor receptor (EGFR) is an oncogene frequently overexpressed in breast cancer (BC), and its overexpression has been associated with poor prognosis and drug resistance. EGFR is therefore a rational target for BC therapy development. This study demonstrated that a graviola fruit extract (GFE) significantly downregulated EGFR gene expression and inhibited the growth of BC cells and xenografts. GFE selectively inhibited the growth of EGFR-overexpressing human BC (MDA-MB-468) cells (IC(50) = 4.8 μg/ml) but had no effect on nontumorigenic human breast epithelial cells (MCF-10A). GFE significantly downregulated EGFR mRNA expression, arrested cell cycle in the G0/G1 phase, and induced apoptosis in MDA-MB-468 cells. In the mouse xenograft model, a 5-wk dietary treatment of GFE (200 mg/kg diet) significantly reduced the protein expression of EGFR, p-EGFR, and p-ERK in MDA-MB-468 tumors by 56%, 54%, and 32.5%, respectively. Overall, dietary GFE inhibited tumor growth, as measured by wet weight, by 32% (P < 0.01). These data showed that dietary GFE induced significant growth inhibition of MDA-MB-468 cells in vitro and in vivo through a mechanism involving the EGFR/ERK signaling pathway, suggesting that GFE may have a protective effect for women against EGFR-overexpressing BC.

No abstract